Can Fite Biofarma Ltd ADR CANF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CANF is a good fit for your portfolio.
News
-
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
-
Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
-
Can-Fite Reports 2023 Financial Results and Clinical Update
-
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
-
Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada
-
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
-
Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study
Trading Information
- Previous Close Price
- $1.97
- Day Range
- $1.96–2.03
- 52-Week Range
- $1.66–3.33
- Bid/Ask
- $1.97 / $2.09
- Market Cap
- $10.13 Mil
- Volume/Avg
- 1,468 / 18,308
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 11.30
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 5
- Website
- http://www.canfite.com
Valuation
|
Metric
|
CANF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.43 |
Price/Sales | 11.30 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CANF
|
|---|---|
Quick Ratio | 4.42 |
Current Ratio | 4.90 |
Interest Coverage | — |
Quick Ratio
CANF
Profitability
|
Metric
|
CANF
|
|---|---|
Return on Assets (Normalized) | −68.82% |
Return on Equity (Normalized) | −116.39% |
Return on Invested Capital (Normalized) | −123.42% |
Return on Assets
CANF
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hcgrfdkdg | Ndf | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Fnglfxpc | Tbvhld | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Smnchcm | Bwcpqt | $98.1 Bil | |
MRNA
| Moderna Inc | Znyfzyll | Jzsnr | $39.1 Bil | |
ARGX
| argenx SE ADR | Yhbfwrcfl | Kwbst | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Dwfhzwcp | Ctt | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Bsjjftgyd | Lsdrrs | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Wcyddhc | Mgnqf | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wflzhjcxr | Zrkpksf | $12.5 Bil | |
INCY
| Incyte Corp | Jrgdtds | Clfpfc | $11.9 Bil |